Advertisement
Advertisement
MNOV
Medicinova, Inc.
1.40
USDSponsored
+0.01
+0.72%
May 01, 16:00 UTC -4
Closed
After-Market
1.40
0.00
-0.21%
MNOV Earnings Reports
Positive Surprise Ratio
MNOV beat 29 of 39 last estimates.
74%
Next Report
Date of Next Report
May 11, 2026
Estimate for Q1 26 (Revenue/ EPS)
--
/-$0.07
Implied change from Q4 25 (Revenue/ EPS)
-100.00%
/+40.00%
Implied change from Q1 25 (Revenue/ EPS)
--
/+16.67%
Medicinova, Inc. earnings per share and revenue
On Mar 10, 2026, MNOV reported earnings of -0.05 USD per share (EPS) for Q4 25, beating the estimate of -0.09 USD, resulting in a 48.40% surprise. Revenue reached 151.74 thousand, compared to an expected --, with a 0.00% difference. The market reacted with a +8.11% price change (close before vs. close after earnings).
Looking ahead to Q1 26, -- analysts forecast an EPS of -0.07 USD, with revenue projected to reach -- USD, implying an increase of 40.00% EPS, and decrease of -100.00% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
NovoCure Limited Ordinary Shares
Report Date
Apr 30, 2026 For Q1 26
Estimate
-$0.52
Actual
-$0.62
Surprise
-18.52%
Phathom Pharmaceuticals, Inc. Common Stock
Report Date
Apr 30, 2026 For Q1 26
Estimate
-$0.32
Actual
-$0.18
Surprise
+45.22%
Pacira BioSciences, Inc. Common Stock
Report Date
Apr 30, 2026 For Q1 26
Estimate
$0.57
Actual
$0.60
Surprise
+4.42%
Emergent Biosolutions, Inc.
Report Date
Apr 30, 2026 For Q1 26
Estimate
-$0.25
Actual
$0.21
Surprise
+183.17%
Amgen Inc
Report Date
Apr 30, 2026 For Q1 26
Estimate
$4.85
Actual
$5.15
Surprise
+6.15%
Bristol-Myers Squibb Co.
Report Date
Apr 30, 2026 For Q1 26
Estimate
$1.42
Actual
$1.58
Surprise
+10.95%
Alnylam Pharmaceuticals, Inc.
Report Date
Apr 30, 2026 For Q1 26
Estimate
$0.95
Actual
$1.99
Surprise
+108.95%
Moderna, Inc. Common Stock
Report Date
May 01, 2026 For Q1 26
Estimate
-$3.32
Actual
-$1.18
Surprise
+64.48%
Illumina Inc
Report Date
Apr 30, 2026 For Q1 26
Estimate
$1.07
Actual
$1.14
Surprise
+6.94%
Bio-Rad Laboratories, Inc. Class B
Report Date
Apr 30, 2026 For Q1 26
Estimate
$2.00
Actual
$1.89
Surprise
-5.68%
FAQ
What were Medicinova, Inc.'s earnings and revenue for the latest quarter Q4 2025?
For Q4 2025, Medicinova, Inc. reported EPS of -$0.05, beating estimates by 48.4%, and revenue of $151.74K, 0% as expectations.
How did the market react to Medicinova, Inc.'s Q4 2025 earnings?
The stock price moved up 8.11%, changed from $1.48 before the earnings release to $1.60 the day after.
When is Medicinova, Inc. expected to report next?
The next earning report is scheduled for May 11, 2026.
What are the forecasts for Medicinova, Inc.'s next earnings report?
Based on --
analysts, Medicinova, Inc. is expected to report EPS of -$0.07 and revenue of -- for Q1 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement